Advertisement

Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study

  • E. A. Underwood
  • K. J. Jerzak
  • G. Lebovic
  • P. A. Rochon
  • C. Elser
  • K. I. Pritchard
  • M. C. TierneyEmail author
Original Article
  • 39 Downloads

Abstract

Purpose

Evidence suggests endocrine therapy (ET) for breast cancer (BC) has adverse cognitive effects, but its specific effects on older women are unknown. This is despite the fact that older women are at increased risk of both breast cancer (BC) and cognitive decline relative to younger women. This study prospectively examined the cognitive effects of ET in a cohort of older BC patients. Our primary outcome measure was change in verbal memory, the cognitive domain most consistently affected by estrogen deprivation.

Methods

Forty-two chemotherapy-naïve women age 60+, without dementia and recently diagnosed with hormone receptor-positive BC, completed neuropsychological tests at the time of ET initiation and after 1 year of treatment. Change in age-standardized verbal memory performance was examined using paired t tests. To assess a broader range of potential cognitive effects, we also examined changes in visual memory, processing speed, frontal executive function, and perceptual reasoning.

Results

Participants exhibited significant decline from baseline to 1 year in verbal memory (p = 0.01). This decline was small to moderate in effect size (d = − 0.40). Performance on other domains did not change significantly over the year (all p > 0.05).

Conclusions

Our findings suggest potentially detrimental effects of ET on verbal memory in older women after just 1 year of treatment. Given that ET is prescribed for courses of 5 to 10 years, additional studies examining longer-term effects of treatment in older women are critical.

Keywords

Breast cancer Cognition Endocrine therapy Verbal memory Aged 

Notes

Acknowledgements

We thank the oncologists, nurses, and radiation therapists at the cancer centers involved in this study for their assistance with patient recruitment. Kathy Zhang (Research Assistant, Sunnybrook Research Institute, Toronto, ON) assisted with data entry. Aspects of this work were presented in poster format at the American Association for Cancer Research Annual Meeting 2018 and were published as an abstract in conference proceedings. This full-text manuscript has not been published elsewhere.

Funding information

This study was supported by a Sunnybrook Alternative Funding Plan Association Innovation Fund. E.A.U. was supported by a Canadian Federation of University Women fellowship and an Ontario Graduate Scholarship during her Master’s training at the Institute of Medical Science, University of Toronto. M.C.T. is supported by a Clinician Scientist award from the Department of Family & Community Medicine, University of Toronto and Sunnybrook Health Sciences Centre. P.A.R holds the Retired Teachers of Ontario/ERO Chair in Geriatric Medicine.

Compliance with ethical standards

Conflict of interest

K.I.P. has served in consulting and advisory roles for and received honoraria and travel support from AstraZeneca, Pfizer, Roche, Amgen, Novartis, and Eisai. K.J.J has served as a consultant for and/or attended advisory boards for Genomic Health Inc., Novartis, Purdue Pharma and Roche. No other authors have any conflicts of interest to report. M.C.T has full control of all primary data and agrees to allow the journal to review the data if requested.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Supplementary material

520_2018_4603_MOESM1_ESM.docx (16 kb)
ESM 1 (DOCX 15.8 kb)

References

  1. 1.
    Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32(21):2255–2269.  https://doi.org/10.1200/jco.2013.54.2258 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    J F IS, M E RD, S E CM, M R DMP, D F FB (2014) GLOBOCAN 2012 v1.1, Cancer incidence and mortality worldwide: IARC CancerBase no. 11 International Agency for Research on Cancer. http://globocan.iarc.fr
  3. 3.
    Anderson WF, Katki HA, Rosenberg PS (2011) Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst 103(18):1397–1402.  https://doi.org/10.1093/jnci/djr257 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Galea LAM, Frick KM, Hampson E, Sohrabji F, Choleris E (2017) Why estrogens matter for behavior and brain health. Neurosci Biobehav Rev 76:369–379.  https://doi.org/10.1016/j.neubiorev.2016.03.024 CrossRefGoogle Scholar
  5. 5.
    Underwood EA, Rochon PA, Moineddin R, Lee PE, Wu W, Pritchard KI, Tierney MC (2017) Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis. Breast Cancer Res Treat 168:299–310.  https://doi.org/10.1007/s10549-017-4627-4 CrossRefPubMedGoogle Scholar
  6. 6.
    Ahles TA, Root JC, Ryan EL (2012) Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol 30(30):3675–3686CrossRefGoogle Scholar
  7. 7.
    Lange M, Rigal O, Clarisse B, Giffard B, Sevin E, Barillet M, Eustache F, Joly F (2014) Cognitive dysfunctions in elderly cancer patients: a new challenge for oncologists. Cancer Treat Rev 40(6):810–817CrossRefGoogle Scholar
  8. 8.
    Mandelblatt JS, Jacobsen PB, Ahles T (2014) Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors. J Clin Oncol 32(24):2617–2626.  https://doi.org/10.1200/jco.2014.55.1259 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lange M, Joly F (2017) How to identify and manage cognitive dysfunction after breast cancer treatment. J Oncol Pract 13(12):784–790.  https://doi.org/10.1200/jop.2017.026286 CrossRefPubMedGoogle Scholar
  10. 10.
    Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB (2010) Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 28(8):1294–1300CrossRefGoogle Scholar
  11. 11.
    Phillips SM, Sherwin BB (1992) Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocr 17(5):485–495.  https://doi.org/10.1016/0306-4530(92)90007-T CrossRefGoogle Scholar
  12. 12.
    Epperson CN, Sammel MD, Freeman EW (2013) Menopause effects on verbal memory: findings from a longitudinal community cohort. J Clin Endocrinol Metab 98(9):3829–3838.  https://doi.org/10.1210/jc.2013-1808 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Zhou G, Liu J, Sun F, Duan L, Yan B, Peng Q (2011) Cognitive functioning in elderly women who underwent unilateral oophorectomy before menopause. Int J Neurosci 121(4):196–200.  https://doi.org/10.3109/00207454.2010.542842 CrossRefPubMedGoogle Scholar
  14. 14.
    American Joint Committee on Cancer (2006) Part IV: breast. In: Greene FL, Compton CC, Fritz AG, Shah JP, Winchester DP (eds) AJCC Cancer Staging Atlas. Springer, New York, pp 217–234Google Scholar
  15. 15.
    Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM, Lipton RB (1999) Screening for dementia with the memory impairment screen. Neurology 52(2):231.  https://doi.org/10.1212/wnl.52.2.231 CrossRefPubMedGoogle Scholar
  16. 16.
    Schmidt M (1996) Rey auditory verbal learning test: RAVLT : a handbook. Western Psychological Services, Los AngelesGoogle Scholar
  17. 17.
    Geffen GM, Butterworth P, Geffen LB (1994) Test-retest reliability of a new form of the auditory verbal learning test. Arch Clin Neuropsychol 9(4):303–316CrossRefGoogle Scholar
  18. 18.
    Benedict RHB, Schretlen D, Groninger L, Dobraski M, Shpritz B (1996) Revision of the brief visuospatial memory test: studies of normal performance, reliability, and validity. Psychol Assess 8(2):145–153CrossRefGoogle Scholar
  19. 19.
    Reitan RM, Woflson D (1985) The halstead–reitan neuropsycholgical test battery: therapy and clinical interpretation. Neuropsychological Press, Tuscon, AZGoogle Scholar
  20. 20.
    Weschler D (2008) Weschler adult intelligence scale-iv. Pearson, New YorkGoogle Scholar
  21. 21.
    Benton AL, Hamsher K, Sivan AB (1994) Multilingual aphasia examination. AJA Associates, Iowa City, IAGoogle Scholar
  22. 22.
    Curran SL, Andrykowski JL, Studts JL (1995) Short form of the profile of mood states (poms–sf): psychometric information. Psychol Assess 7(1):80–83CrossRefGoogle Scholar
  23. 23.
    Simon R, Latreille J, Matte C, Desjardins P, Bergeron E (2014) Adherence to adjuvant endocrine therapy in estrogen receptor–positive breast cancer patients with regular follow-up. Can J Surg 57(1):26–32.  https://doi.org/10.1503/cjs.006211 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Harrell FE (2015) Multivariable modeling strategies. In: Regression Modeling Strategies. Second edn. Springer, Cham, pp 53–85Google Scholar
  25. 25.
    Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S (2009) Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psycho-Oncology 18(8):811–821CrossRefGoogle Scholar
  26. 26.
    Hedayati E, Alinaghizadeh H, Schedin A, Nyman H, Albertsson M (2012) Effects of adjuvant treatment on cognitive function in women with early breast cancer. Eur J Oncol Nurs 16(3):315–322CrossRefGoogle Scholar
  27. 27.
    Debess J, Riis JO, Engebjerg MC, Ewertz M (2010) Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat 121(1):91–100CrossRefGoogle Scholar
  28. 28.
    Hurria A, Patel SK, Mortimer J, Luu T, Somlo G, Katheria V, Ramani R, Hansen K, Feng T, Chuang C, Geist CL, Silverman DH (2014) The effect of aromatase inhibition on the cognitive function of older patients with breast cancer. Clin Breast Cancer 14(2):132–140CrossRefGoogle Scholar
  29. 29.
    Ganz PA, Petersen L, Castellon SA, Bower JE, Silverman DH, Cole SW, Irwin MR, Belin TR (2014) Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study. J Clin Oncol 32(31):3559–3567CrossRefGoogle Scholar
  30. 30.
    Yesufu A, Bandelow S, Hogervorst E (2007) Meta-analyses of the effect of hormone treatment on cognitive function in postmenopausal women. Womens Health (Lond) 3(2):173–194.  https://doi.org/10.2217/17455057.3.2.173 CrossRefGoogle Scholar
  31. 31.
    LeBlanc ES, Janowsky J, Chan BK, Nelson HD (2001) Hormone replacement therapy and cognition: systematic review and meta-analysis. J Am Med Assoc 285(11):1489–1499CrossRefGoogle Scholar
  32. 32.
    Wolf OT, Kirschbaum C (2002) Endogenous estradiol and testosterone levels are associated with cognitive performance in older women and men. Horm Behav 41(3):259–266.  https://doi.org/10.1006/hbeh.2002.1770 CrossRefPubMedGoogle Scholar
  33. 33.
    Hogervorst E, De Jager C, Budge M, Smith AD (2004) Serum levels of estradiol and testosterone and performance in different cognitive domains in healthy elderly men and women. Psychoneuroendocr 29(3):405–421CrossRefGoogle Scholar
  34. 34.
    Drake EB, Henderson VW, Stanczyk FZ, McCleary CA, Brown WS, Smith CA, Rizzo AA, Murdock GA, Buckwalter JG (2000) Associations between circulating sex steroid hormones and cognition in normal elderly women. Neurology 54(3):599–603CrossRefGoogle Scholar
  35. 35.
    Tierney MC, Moineddin R, McDowell I (2010) Prediction of all-cause dementia using neuropsychological tests within 10 and 5 years of diagnosis in a community-based sample. J Alzheimers Dis 22(4):1231–1240.  https://doi.org/10.3233/jad-2010-100516 CrossRefPubMedGoogle Scholar
  36. 36.
    Tierney MC, Yao C, Kiss A, McDowell I (2005) Neuropsychological tests accurately predict incident Alzheimer’s disease after five and ten years. Neurology 64:1853–1859CrossRefGoogle Scholar
  37. 37.
    Rabin LA, Paré N, Saykin AJ, Brown MJ, Wishart HA, Flashman LA, Santulli RB (2009) Differential memory test sensitivity for diagnosing amnestic mild cognitive impairment and predicting conversion to Alzheimer’s disease. Neuropsychology, development, and cognition section B, aging, neuropsychology and cognition. 16(3):357–376.  https://doi.org/10.1080/13825580902825220
  38. 38.
    Andreotti C, Root JC, Schagen SB, McDonald BC, Saykin AJ, Atkinson TM, Li Y, Ahles TA (2016) Reliable change in neuropsychological assessment of breast cancer survivors. Psychooncology 25(1):43–50.  https://doi.org/10.1002/pon.3799 CrossRefPubMedGoogle Scholar
  39. 39.
    Phillips KA, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V, Thurlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J (2010) Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the big 1-98 randomized trial. Breast 19(5):388–395CrossRefGoogle Scholar
  40. 40.
    Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, Cohen SM, Casillo FE, Berga SL (2007) Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 14(6):995–998.  https://doi.org/10.1097/gme.0b013e318148b28b CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Primary Care Research Unit, Department of Family and Community MedicineSunnybrook Health Sciences CentreTorontoCanada
  2. 2.Sunnybrook Research InstituteTorontoCanada
  3. 3.Odette Cancer CentreSunnybrook Health Sciences CentreTorontoCanada
  4. 4.Institute of Health Policy, Management and EvaluationUniversity of TorontoTorontoCanada
  5. 5.Applied Health Research CentreSt. Michael’s HospitalTorontoCanada
  6. 6.Department of MedicineUniversity of TorontoTorontoCanada
  7. 7.Women’s College Research InstituteWomen’s College HospitalTorontoCanada
  8. 8.Princess Margaret Hospital Cancer CentreTorontoCanada
  9. 9.Sinai Health SystemTorontoCanada
  10. 10.Department of Family & Community MedicineUniversity of TorontoTorontoCanada

Personalised recommendations